Your browser is no longer supported. Please, upgrade your browser.
Settings
BCYC Bicycle Therapeutics plc daily Stock Chart
BCYC [NASD]
Bicycle Therapeutics plc
Index- P/E- EPS (ttm)-1.92 Insider Own33.73% Shs Outstand17.63M Perf Week-2.44%
Market Cap197.46M Forward P/E- EPS next Y-2.06 Insider Trans0.00% Shs Float4.33M Perf Month20.11%
Income-34.20M PEG- EPS next Q-0.52 Inst Own35.80% Short Float0.28% Perf Quarter18.14%
Sales9.60M P/S20.57 EPS this Y-34.50% Inst Trans- Short Ratio0.34 Perf Half Y27.42%
Book/sh5.33 P/B2.10 EPS next Y23.70% ROA-34.00% Target Price19.60 Perf Year-
Cash/sh5.45 P/C2.06 EPS next 5Y- ROE-248.10% 52W Range6.24 - 14.91 Perf YTD18.77%
Dividend- P/FCF- EPS past 5Y- ROI30.60% 52W High-24.88% Beta-
Dividend %- Quick Ratio12.50 Sales past 5Y- Gross Margin- 52W Low79.48% ATR0.83
Employees61 Current Ratio12.50 Sales Q/Q-90.20% Oper. Margin- RSI (14)58.74 Volatility6.69% 9.36%
OptionableNo Debt/Eq0.00 EPS Q/Q32.50% Profit Margin- Rel Volume0.22 Prev Close11.10
ShortableYes LT Debt/Eq0.00 EarningsFeb 06 Payout- Avg Volume34.95K Price11.20
Recom1.60 SMA203.77% SMA5018.69% SMA20017.47% Volume7,771 Change0.90%
Nov-14-19Initiated ROTH Capital Buy $17
Sep-11-19Upgrade Goldman Neutral → Buy $14
Jun-17-19Initiated Piper Jaffray Overweight $20
Jun-17-19Initiated Jefferies Buy $22
Jun-17-19Initiated Goldman Neutral $14
Jun-17-19Initiated Canaccord Genuity Buy $22
Jan-07-20 07:00AM  Bicycle Therapeutics and Cancer Research UK to Collaborate on Development of New Bicycle® Immuno-oncology Candidate, BT7401 Business Wire +10.47%
Dec-22-19 06:09PM  Is Bicycle Therapeutics plc (BCYC) Going to Burn These Hedge Funds? Insider Monkey
Nov-26-19 07:00AM  Bicycle Therapeutics to Present at the Piper Jaffray 31st Annual Healthcare Conference TEST Business Wire Releases
07:00AM  Bicycle Therapeutics to Present at the Piper Jaffray 31st Annual Healthcare Conference Business Wire
Nov-14-19 07:00AM  Bicycle Therapeutics to Present at the Jefferies 2019 London Healthcare Conference Business Wire +8.65%
Nov-13-19 07:00AM  Bicycle Therapeutics Announces First Patient Dosed in Phase I/II Trial of Bicycle® Toxin Conjugate BT5528 in Patients with Advanced Solid Tumors Business Wire +5.84%
Nov-07-19 07:00AM  Bicycle Therapeutics Reports Third Quarter 2019 Financial Results and Corporate Update Business Wire
Nov-05-19 08:14AM  Bicycle Therapeutics to Present New Preclinical Data on BT7480, a Novel, Fully Synthetic Bicycle® Tumor-targeted Immune Cell Agonist, at the Society for Immunotherapy of Cancers 2019 Annual Meeting Business Wire -12.61%
Oct-31-19 07:00AM  Bicycle Therapeutics Announces Appointment of Veronica Jordan, Ph.D., to Board of Directors Business Wire
Oct-29-19 07:00AM  Bicycle Therapeutics Announces Appointment of Nigel Crockett, Ph.D., as Chief Business Officer Business Wire
Oct-22-19 03:00AM  Bicycle Therapeutics Expands Neuroscience Collaborations to Include Oxford Universitys Oxford Drug Discovery Institute Business Wire
Oct-16-19 04:33PM  Bicycle Therapeutics to Present New Translational Data for BT1718 and Preclinical Data for Other Bicycle® Toxin Conjugates at AACR-NCI-EORTC 2019 Business Wire
Sep-28-19 06:00AM  Bicycle Therapeutics Announces Presentation of Updated Data from Phase I/IIa Trial Evaluating BT1718 in Patients with Advanced Solid Tumors at ESMO 2019 Annual Congress Business Wire
Sep-24-19 07:00AM  Bicycle Therapeutics to Present Updated Data from Phase I/IIa Trial Evaluating Lead Asset BT1718 in Patients with Advanced Solid Tumors at ESMO 2019 Annual Congress Business Wire
Sep-19-19 09:23AM  When Will Bicycle Therapeutics plc (NASDAQ:BCYC) Run Out Of Cash? Simply Wall St. -15.90%
Aug-08-19 07:00AM  Bicycle Therapeutics Reports Second Quarter 2019 Financial Results and Provides Clinical Update Business Wire
Jul-24-19 08:00AM  Bicycle Therapeutics Enhances Board of Directors Business Wire
Jul-01-19 07:46AM  Bicycle Therapeutics shares soar 29% premarket on news of positive trial of DME treatment MarketWatch
07:30AM  Bicycle Therapeutics Announces Positive Topline Results from Oxurions Phase I Trial Using a Novel Bicycle-based Plasma Kallikrein Inhibitor for the Treatment of Diabetic Macular Edema Business Wire
May-23-19 01:09PM  Bicycle Therapeutics shares slide 10.7% in trading debut MarketWatch
09:15AM  Guest Host Tonight and Tomorrow Zacks
08:55AM  Bicycle Therapeutics raises $60.2 million in IPO, Ideaya Biosciences raises $50 million MarketWatch
May-22-19 09:49PM  Bicycle Therapeutics Announces Pricing of Initial Public Offering Business Wire
May-21-19 04:45PM  Bicycle Therapeutics IPO: What You Need To Know Benzinga
Bicycle Therapeutics Limited, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in preclinical studies targeting EphA2; BT8009, which is in preclinical studies targeting Nectin-4; and CD137, an immune cell co-stimulatory molecule that is in preclinical stage, as well as systemically-delivered activators. In addition, it is developing THR-149, a key immune cell co-stimulatory molecule that is in Phase I clinical trials. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, hematology, ophthalmology, and respiratory indications. The company has a clinical trial and license agreement with the Cancer Research Technology Limited and CRUK; and research collaboration agreement with Bioverativ Inc., AstraZeneca AB, and Oxurion NV. The company was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.